Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Dren Bio
Quetzal Therapeutics
National Institutes of Health Clinical Center (CC)
AVM Biotechnology Inc
Children's Hospital of Philadelphia
Orca Biosystems, Inc.
Ohio State University Comprehensive Cancer Center
Kura Oncology, Inc.
Novartis
First Affiliated Hospital of Zhejiang University
M.D. Anderson Cancer Center
Kura Oncology, Inc.
Arovella Therapeutics Ltd
St. Justine's Hospital
Georgetown University
Dana-Farber Cancer Institute
Taiho Oncology, Inc.
Eastern Cooperative Oncology Group
Medical College of Wisconsin
CRISPR Therapeutics
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
AvenCell Therapeutics, Inc.
Takeda
H. Lee Moffitt Cancer Center and Research Institute
Daiichi Sankyo
University of Chicago
Vironexis Biotherapeutics Inc.
Memorial Sloan Kettering Cancer Center
Karolinska University Hospital
Dana-Farber Cancer Institute
City of Hope Medical Center
University of Nebraska
Novartis
Pfizer
Thomas Jefferson University
Fate Therapeutics
Syndax Pharmaceuticals
Center for International Blood and Marrow Transplant Research
Dana-Farber Cancer Institute